IceCure Successfully Completes First Cryoablation Treatment in Its ChoICE Post-Marketing Study for Breast Cancer Cryoablation
IceCure Medical (ICCM) announced the successful treatment of the first patient in its ChoICE post-marketing study for breast cancer cryoablation. The study, led by West Cancer Center in Tennessee, aims to enroll 400 patients across 30 U.S. sites. The company's ProSense® system is FDA-cleared for specific breast cancer treatments. IceCure expects the study to support broader adoption of its cryoablation technology.
How this was made

The 30-second read
Why it matters
The announcement provides the first concrete data point of the study’s execution, signaling progress toward broader commercial adoption.
Market read
First patient treatment is a material milestone for a micro‑cap biotech, likely generating short‑term buying interest.
What to watch
Potential regulatory scrutiny or reimbursement challenges could dampen long‑term upside.
Background
IceCure Medical (NASDAQ: ICCM) develops liquid‑nitrogen cryoablation systems. The ChoICE study will enroll ~400 patients across up to 30 US sites to generate real‑world data on its FDA‑cleared ProSense® system for low‑risk breast cancer.
Ticker impact
IceCure Medical announced the first patient treatment in its ChoICE post‑marketing study for breast cancer cryoablation.
likely upward pressure as the market prices in the successful start of the study
First‑in‑human treatment is a material, novel event for a micro‑cap biotech; investors typically react positively to clinical progress.
Market effects
May increase interest in cryoablation technologies and related med‑tech stocks.
Limited to US biotech sector; no broader regional effect.
Low; relevance confined to niche oncology device market.
Counterpoint
If the study fails to enroll or shows limited efficacy, the initial hype could reverse quickly.
Key entities
- companyIceCure Medical Ltd.
Developer of the ProSense® cryoablation system.
- institutionWest Cancer Center & Research Institute
Site of the first patient treatment.

